Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma

Giancarlo Bisagni, Giulio Rossi, Alberto Cavazza, Giuliana Sartori, Giorgio Gardini, Corrado Boni

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Metastatic thymic carcinoma is an aggressive neoplasm for which multimodal therapies are often ineffective. We describe here a heavily pretreated patient with advanced thymic carcinoma responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). Of note, a hitherto unreported c-kit missense mutation on exon 17 (D820E) identified in tumor cells seems to explain the clinical response and highlight the key role of molecular analysis in predicting efficacy of targeted therapies even in thymic neoplasms.

Original languageEnglish
Pages (from-to)773-775
Number of pages3
JournalJournal of Thoracic Oncology
Volume4
Issue number6
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Thymoma
Thymus Neoplasms
Missense Mutation
Exons
Neoplasms
Therapeutics
sorafenib

Keywords

  • C-Kit
  • CD117
  • Thymic carcinoma
  • Thymoma
  • Tyrosine kinase

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. / Bisagni, Giancarlo; Rossi, Giulio; Cavazza, Alberto; Sartori, Giuliana; Gardini, Giorgio; Boni, Corrado.

In: Journal of Thoracic Oncology, Vol. 4, No. 6, 06.2009, p. 773-775.

Research output: Contribution to journalArticle

@article{6a864f1a889e4a648fd7d1b99f6f17aa,
title = "Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma",
abstract = "Metastatic thymic carcinoma is an aggressive neoplasm for which multimodal therapies are often ineffective. We describe here a heavily pretreated patient with advanced thymic carcinoma responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). Of note, a hitherto unreported c-kit missense mutation on exon 17 (D820E) identified in tumor cells seems to explain the clinical response and highlight the key role of molecular analysis in predicting efficacy of targeted therapies even in thymic neoplasms.",
keywords = "C-Kit, CD117, Thymic carcinoma, Thymoma, Tyrosine kinase",
author = "Giancarlo Bisagni and Giulio Rossi and Alberto Cavazza and Giuliana Sartori and Giorgio Gardini and Corrado Boni",
year = "2009",
month = "6",
doi = "10.1097/JTO.0b013e3181a52e25",
language = "English",
volume = "4",
pages = "773--775",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma

AU - Bisagni, Giancarlo

AU - Rossi, Giulio

AU - Cavazza, Alberto

AU - Sartori, Giuliana

AU - Gardini, Giorgio

AU - Boni, Corrado

PY - 2009/6

Y1 - 2009/6

N2 - Metastatic thymic carcinoma is an aggressive neoplasm for which multimodal therapies are often ineffective. We describe here a heavily pretreated patient with advanced thymic carcinoma responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). Of note, a hitherto unreported c-kit missense mutation on exon 17 (D820E) identified in tumor cells seems to explain the clinical response and highlight the key role of molecular analysis in predicting efficacy of targeted therapies even in thymic neoplasms.

AB - Metastatic thymic carcinoma is an aggressive neoplasm for which multimodal therapies are often ineffective. We describe here a heavily pretreated patient with advanced thymic carcinoma responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). Of note, a hitherto unreported c-kit missense mutation on exon 17 (D820E) identified in tumor cells seems to explain the clinical response and highlight the key role of molecular analysis in predicting efficacy of targeted therapies even in thymic neoplasms.

KW - C-Kit

KW - CD117

KW - Thymic carcinoma

KW - Thymoma

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=67849108379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67849108379&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181a52e25

DO - 10.1097/JTO.0b013e3181a52e25

M3 - Article

C2 - 19461405

AN - SCOPUS:67849108379

VL - 4

SP - 773

EP - 775

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -